Endocrine Abstracts

Introduction: medullary thyroid carcinoma (MTC) is a neuroendocrine thyroidal cancer. World Health Organization recognizes a grading system for almost all neuroendocrine tumors; however, a shared grading system for MTC is still lacking. We performed a clinical and pathological review of 257 MTCs to evaluate which histologic features have an impact on the disease specific survival and to propose a new grading system.Method: We retrospectively reviewed cli...

Background: Cervical lymph node metastases at histology are common findings in differentiated thyroid cancer (DTC); however, their impact on clinical outcome is debated.Material and method: 1332 DTC patients, performed the first 131 I treatment between January 2010 and September 2012 and were divided into 2 groups: absence (Nx/N0) or presence (N1) of lymph node metastases at histology. The latter group was further split in central compartment ...

Background: Serum calcitonin (CT) is a very sensitive test for the diagnosis of medullary thyroid carcinoma (MTC). However, its routine dosage in patients with nodular thyroid disease is not recommended by all scientific societies. In addition, to optimize costs, it is only suggested in the case of suspicious nodules on ultrasound, indeterminate nodules at cytology or nodular goiter before surgery. The aim of the study is to evaluate the serum CT in a series of consecutive MTC...

Introduction: MTC is a rare neuroendocrine tumor arising from thyroid parafollicular cells. After initial treatment, patients should be divided according to their clinical status in cured, biochemical persistence (BIO) and structural persistence (STR) of the disease. Concerning BIO patients less is known about the structural disease appearance rate and the time elapsed between the first evaluation after surgery and the appearance of structural disease.Me...

Background: Since 2006 according to the European consensus for the management of patients with DTC, in tumors ≤ 1 cm, treatment with thyroidectomy alone without 131I treatment was suggested. Therefore, in our institution, we applied this suggestion in clinical practice, although prospective studies were not still available. Aim of this study is to evaluate the rate of the events occurring in a medium-long term follow-up.Patients and Meth...

Background: Lymph node metastases at histology (pN1) are usual findings in differentiated thyroid cancer (DTC) patients. Their detection has an impact on the extent of surgery, the further treatments after surgery, and on the clinical outcome.Material and method: We evaluated data of 1332 consecutive DTC patients who performed the first 131I treatment between January 2010 and September 2012. According to their pN status, they were divided into...

Introduction: An increased Body Mass Index (BMI) has been associated with higher prevalence of many cancers, including differentiated thyroid cancer. However, no data have been reported about potential impact of BMI on aggressiveness of presentation and clinical outcome of medullary thyroid cancer (MTC).Aim: To evaluate the potential influence of BMI on clinical presentation and outcome of MTC.Methods: We reviewed anthropometric an...

Objectives: Vandetanib (V) is an important drug in the metastatic medullary thyroid cancer (MTC) treatment. The objective of this study was to evaluate the presence of predictors of V response, in short and long period, in locally advanced or metastatic MTC patients (pts).Methods: Seventy-nine locally advanced or metastatic MTC pts with progressive or symptomatic disease, referred to our Center between 2007 and 2018 and already treated surgically and wit...

Background: CV-PTC is often indolent with excellent long-term response, while TCV-PTC (≥50% of tall cells) have aggressive features and worse clinical behavior. Less is known about the clinical behavior of CV-PTC with tall cells <50% (TC/CV-PTC) that, so far, is considered as low risk tumor.Aim: To evaluate the histological presentation of CV-PTC, TC/CV-PTC, TCV-PTC and their clinical behavior after 6 years of follow up.M...

Patients with chronic hypoparathyroidism (HypoPT) treated with oral calcium and active vitamin D metabolites are at risk of renal complications, because of the lack of action of PTH at the renal tubule. In the present study we evaluated 90 patients (68 females and 22 males; age: 51.8±14.1 yrs) with chronic postoperative Hypo (PO-HypoPT) diagnosed since at least 3 years. All patients were treated with calcitriol and 35 (39%) with oral calcium two patients were also treated...